Table of Contents Author Guidelines Submit a Manuscript
International Journal of Genomics
Volume 2017 (2017), Article ID 2790864, 12 pages
https://doi.org/10.1155/2017/2790864
Research Article

Lingguizhugan Decoction Protects against High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress and Activating Cholesterol Secretion

1Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases (ccCRDD), Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
2Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200032, China
3University of Chinese Academy of Sciences, Beijing 100049, China
4Digestive Diseases and Nutrition Center, Women and Children’s Hospital of Buffalo, Department of Pediatrics, The State University of New York at Buffalo, Buffalo, NY 14214, USA

Correspondence should be addressed to Tao Liu and Peiyong Zheng

Received 2 June 2017; Revised 11 September 2017; Accepted 7 November 2017; Published 31 December 2017

Academic Editor: Peijian He

Copyright © 2017 Lili Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Wree, L. Broderick, A. Canbay, H. M. Hoffman, and A. E. Feldstein, “From NAFLD to NASH to cirrhosis–new insights into disease mechanisms,” Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 11, pp. 627–636, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. C. P. Day and O. F. James, “Steatohepatitis: a tale of two “hits”?” Gastroenterology, vol. 114, no. 4, pp. 842–845, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Zhu, S. S. Baker, C. Gill et al., “Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH,” Hepatology, vol. 57, no. 2, pp. 601–609, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Zhu, R. D. Baker, R. Zhu, and S. S. Baker, “Gut microbiota produce alcohol and contribute to NAFLD,” Gut, vol. 65, no. 7, article 1232, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Zhang, S. S. Baker, R. D. Baker, R. Zhu, and L. Zhu, “Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism,” PLoS One, vol. 7, no. 12, article e51131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Zhu, S. S. Baker, C. A. Moylan et al., “Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers,” The Journal of Pathology, vol. 238, no. 4, pp. 531–542, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. S. S. Baker, R. D. Baker, W. Liu, N. J. Nowak, and L. Zhu, “Role of alcohol metabolism in non-alcoholic steatohepatitis,” PLoS One, vol. 5, no. 3, article e9570, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Sozen and N. K. Ozer, “Impact of high cholesterol and endoplasmic reticulum stress on metabolic diseases: an updated mini-review,” Redox Biology, vol. 12, pp. 456–461, 2017. View at Publisher · View at Google Scholar
  9. L. Zhu, R. D. Baker, and S. S. Baker, “Editorial: from multiple hits to multiple therapeutic targets of non-alcoholic fatty liver disease,” Current Drug Targets, vol. 16, no. 12, pp. 1272-1273, 2015. View at Publisher · View at Google Scholar
  10. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” New England Journal of Medicine, vol. 362, no. 18, pp. 1675–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Q. Feng, W. Liu, S. S. Baker et al., “Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease,” Oncotarget, vol. 8, no. 17, pp. 27820–27838, 2017. View at Publisher · View at Google Scholar
  12. J.-Y. Xu, L. Zhang, Z.-P. Li, and G. Ji, “Natural products on nonalcoholic fatty liver disease,” Current Drug Targets, vol. 16, no. 12, pp. 1347–1355, 2015. View at Publisher · View at Google Scholar
  13. D. Chen, B. Ke, Y. Huang et al., “Effects of the modified Linggui Zhugan Decoction () combined with short-term very low calorie diets on glycemic control in newly diagnosed type 2 diabetics,” Journal of Traditional Chinese Medicine, vol. 31, no. 3, pp. 185–188, 2011. View at Publisher · View at Google Scholar
  14. T. Liu, L.-L. Yang, L. Zou et al., “Chinese medicine formula Lingguizhugan decoction improves beta-oxidation and metabolism of fatty acid in high-fat-diet-induced rat model of fatty liver disease,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 429738, pp. 1–9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Wang, W. Lin, C. Li et al., “Multipronged therapeutic effects of Chinese herbal medicine Qishenyiqi in the treatment of acute myocardial infarction,” Frontiers in Pharmacology, vol. 8, p. 98, 2017. View at Publisher · View at Google Scholar
  16. C. X. Chen, Pharmacology of Traditional Chinese Medicine, Shanghai Scientific and Technical Publishers, Shanghai, China, 2006.
  17. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Gawrieh, M. C. Marion, R. Komorowski et al., “Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD,” Digestive Diseases and Sciences, vol. 57, no. 4, pp. 952–957, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. C. Kim and J. M. Ntambi, “Regulation of stearoyl-CoA desaturase genes: role in cellular metabolism and preadipocyte differentiation,” Biochemical and Biophysical Research Communications, vol. 266, no. 1, pp. 1–4, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Ntambi, “Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol,” Journal of Lipid Research, vol. 40, no. 9, pp. 1549–1558, 1999. View at Google Scholar
  21. P. Marzuillo, A. Grandone, L. Perrone, and E. M. del Giudice, “Understanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: the role of genetics,” World Journal of Hepatology, vol. 7, no. 11, article 1439, 1443 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. A. M. Hamed, O. A. El-Kharashi, S. S. Boctor, and L. F. Abd-Elaziz, “Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: accuracy of non-invasive panel in determining the stage of liver fibrosis in rats,” Biomedicine & Pharmacotherapy, vol. 85, pp. 68–78, 2017. View at Publisher · View at Google Scholar
  23. A. Federico, M. Dallio, M. Masarone, M. Persico, and C. Loguercio, “The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction,” European Review for Medical and Pharmacological Sciences, vol. 20, no. 22, pp. 4731–4741, 2016. View at Google Scholar
  24. K. H. Liss and B. N. Finck, “PPARs and nonalcoholic fatty liver disease,” Biochimie, vol. 136, pp. 65–74, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Verdelho Machado and A. M. Diehl, “Role of hedgehog signaling pathway in NASH,” International Journal of Molecular Sciences, vol. 17, no. 6, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. M. V. Machado, G. A. Michelotti, G. Xie et al., “Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease,” PLoS One, vol. 10, no. 5, article e0127991, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. C. D. Guy, A. Suzuki, M. Zdanowicz et al., “Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease,” Hepatology, vol. 55, no. 6, pp. 1711–1721, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Kwon, K. Song, C. Han et al., “Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease,” Hepatology, vol. 63, no. 4, pp. 1155–1169, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Hirsova, S. H. Ibrahim, S. F. Bronk, H. Yagita, and G. J. Gores, “Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis,” PLoS One, vol. 8, no. 7, article e70599, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. W. K. Syn, Y. Jung, A. Omenetti et al., “Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease,” Gastroenterology, vol. 137, no. 4, pp. 1478–1488.e8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Huynh, C. Ng, C. Ong, K. Lim, and T. M. Chan, “Cloning and characterization of a novel pregnancy-induced growth inhibitor in mammary gland,” Endocrinology, vol. 142, no. 8, pp. 3607–3615, 2001. View at Publisher · View at Google Scholar
  32. M. Liu, Y. Li, L. Chen et al., “Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma,” Gastroenterology, vol. 146, no. 4, pp. 1084–1096.e5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. J. He, B. Hu, X. Shi et al., “Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3,” Molecular and cellular biology, vol. 33, no. 10, pp. 2047–2055, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. T. P. Dalton, A. Puga, and H. G. Shertzer, “Induction of cellular oxidative stress by aryl hydrocarbon receptor activation,” Chemico-Biological Interactions, vol. 141, no. 1-2, pp. 77–95, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. J. H. Lee, T. Wada, M. Febbraio et al., “A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis,” Gastroenterology, vol. 139, no. 2, pp. 653–663, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Lu, W. Cui, and C. D. Klaassen, “Nrf2 protects against 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis,” Toxicology and Applied Pharmacology, vol. 256, no. 2, pp. 122–135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. J. He, J. H. Lee, M. Febbraio, and W. Xie, “The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease,” Experimental Biology and Medicine, vol. 236, no. 10, pp. 1116–1121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Wahlang, M. Song, J. I. Beier et al., “Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease,” Toxicology and Applied Pharmacology, vol. 279, no. 3, pp. 380–390, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. L. R. Ferreira, E. F. Abrantes, C. V. Rodrigues et al., “Identification and characterization of a novel mouse gene encoding a Ras-associated guanine nucleotide exchange factor: expression in macrophages and myocarditis elicited by Trypanosoma cruzi parasites,” Journal of Leukocyte Biology, vol. 72, no. 6, pp. 1215–1227, 2002. View at Google Scholar
  40. S. Ceccarelli, N. Panera, M. Mina et al., “LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease,” Oncotarget, vol. 6, no. 39, pp. 41434–41452, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. M. D. Keller, R. Pandey, D. Li et al., “Mutation in IRF2BP2 is responsible for a familial form of common variable immunodeficiency disorder,” Journal of Allergy and Clinical Immunology, vol. 138, no. 2, pp. 544–550.e4, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. J. S. Bae, J. M. Park, J. Lee et al., “Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice,” Metabolism, vol. 66, pp. 32–44, 2017. View at Publisher · View at Google Scholar
  43. J. M. Wang, D. Wang, Y. Y. Tan, G. Zhao, and Z. L. Ji, “Pioglitazone reduces lipid droplets in cholesterolosis of the gallbladder by increasing ABCA1 and NCEH1 expression,” Molecular and Cellular Biochemistry, vol. 399, no. 1-2, pp. 7–15, 2015. View at Publisher · View at Google Scholar · View at Scopus